



## 2023 Medicare Part D Formulary Change

We may add or remove drugs from our formulary during the year. If we remove drugs from our formulary, or add prior authorizations, quantity limits and/or step therapy restrictions on a drug (or move a drug to a higher cost-sharing tier), we will let you know of the change. However, if the Food and Drug Administration deems a drug on our formulary to be unsafe or the drug's manufacturer removes the drug from the market, we will immediately remove the drug from our formulary and let you know.

The product changes noted below will be implemented on the Medicare Part D Plan formulary.

To see if your drug is on this list, please refer to the tables below

### New Added Products: **Effective 11/1/2023**

Drug	Restrictions*
INPEFA 200 MG TABLET	PA QL
TIOTROPIUM BROMIDE 18 MCG CAPSULE WITH INHALATION DEVICE	QL

### New Added Products: **Effective 10/1/2023**

Drug	Restrictions*
ABRYSVO 120 MCG/0.5 ML INTRAMUSCULAR SOLUTION	
ADALIMUMAB-ADAZ 40 MG/0.4 ML SUBCUTANEOUS PEN INJECTOR	PA QL
ADALIMUMAB-ADAZ 40 MG/0.4 ML SUBCUTANEOUS SYRINGE	PA QL
AREXVY (PF) 120 MCG/0.5 ML IM SUSPENSION	
BUDESONIDE-FORMOTEROL HFA 160 MCG-4.5 MCG/ACTUATION AEROSOL INHALER	QL
BUDESONIDE-FORMOTEROL HFA 80 MCG-4.5 MCG/ACTUATION AEROSOL INHALER	QL
TALZENNA 0.1 MG CAPSULE	PA QL
TALZENNA 0.35 MG CAPSULE	PA QL
VIGADRONE 500 MG TABLET	LA

Updated: 11/1/2023

Y0026\_203589\_C

EmblemHealth Plan Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies. EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



Drug	Restrictions*
ZEJULA 100 MG TABLET	PA QL LA
ZEJULA 200 MG TABLET	PA QL LA
ZEJULA 300 MG TABLET	PA QL LA
ZEPOSIA STARTER KIT (28-DAY) 0.23 MG-0.46 MG-0.92 MG CAPSULES DOSEPACK	PA QL

New Added Products: **Effective 9/1/2023**

Drug	Restrictions*
ABILIFY ASIMTUFII 720 MG/2.4 ML SUSPENSION, EXTEND.REL. IM SYRINGE	QL
ABILIFY ASIMTUFII 960 MG/3.2 ML SUSPENSION, EXTEND.REL. IM SYRINGE	QL
CYLTEZO(CF) 10 MG/0.2 ML SUBCUTANEOUS SYRINGE KIT	PA QL
CYLTEZO(CF) 20 MG/0.4 ML SUBCUTANEOUS SYRINGE KIT	PA QL
CYLTEZO(CF) 40 MG/0.8 ML SUBCUTANEOUS SYRINGE KIT	PA QL
CYLTEZO(CF) PEN 40 MG/0.8 ML SUBCUTANEOUS KIT	PA QL
CYLTEZO(CF) PEN CROHN-ULC COLITIS-HID SUP STRT 40 MG/0.8 ML SUBCUT KIT	PA QL
CYLTEZO(CF) PEN PSORIASIS STARTER 40 MG/0.8 ML SUBCUTANEOUS KIT	PA QL
DARUNAVIR ETHANOLATE 600 MG TABLET	
DARUNAVIR ETHANOLATE 800 MG TABLET	
GRALISE 450 MG TABLET,EXTENDED RELEASE	PA QL
GRALISE 750 MG TABLET,EXTENDED RELEASE	PA QL
GRALISE 900 MG TABLET,EXTENDED RELEASE	PA QL
HYRIMOZ(CF) 10 MG/0.1 ML SUBCUTANEOUS SYRINGE	PA QL
HYRIMOZ(CF) 20 MG/0.2 ML SUBCUTANEOUS SYRINGE	PA QL
HYRIMOZ(CF) 40 MG/0.4 ML SUBCUTANEOUS SYRINGE	PA QL
YRIMOZ(CF) PEDI CROHNS START 80 MG/0.8 ML-40 MG/0.4 ML SUBCUT SYRINGE	PA QL

Updated: 11/1/2023

Y0026\_203589\_C

EmblemHealth Plan Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies. EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



Drug	Restrictions*
HYRIMOZ(CF) PEN 40 MG/0.4 ML SUBCUTANEOUS PEN INJECTOR	PA QL
HYRIMOZ(CF) PEN 80 MG/0.8 ML SUBCUTANEOUS PEN INJECTOR	PA QL
HYRIMOZ(CF) PEN CROHN-ULC COLITIS START 80MG/0.8ML SUBCUT PEN INJECTOR	PA QL
HYRIMOZ(CF) PEN PSORIASIS START 80MG/0.8ML(1)-40MG/0.4ML(2) SUBCUT PEN	PA QL
LUPRON DEPOT-PED 11.25 MG (3 MONTH) INTRAMUSCULAR SYRINGE KIT	PA
LUPRON DEPOT-PED 45 MG INTRAMUSCULAR SYRINGE KIT	PA
LUPRON DEPOT-PED 7.5 MG (PED) INTRAMUSCULAR KIT	PA
NEXPLANON 68 MG SUBDERMAL IMPLANT	
UZEDY 100 MG/0.28 ML SUBCUT EXT REL SUSPENSION SYRINGE	QL
UZEDY 125 MG/0.35 ML SUBCUT EXT REL SUSPENSION SYRINGE	QL
UZEDY 150 MG/0.42 ML SUBCUT EXT REL SUSPENSION SYRINGE	QL
UZEDY 200 MG/0.56 ML SUBCUT EXT REL SUSPENSION SYRINGE	QL
UZEDY 250 MG/0.7 ML SUBCUT EXT REL SUSPENSION SYRINGE	QL
UZEDY 50 MG/0.14 ML SUBCUT EXT REL SUSPENSION SYRINGE	QL
UZEDY 75 MG/0.21 ML SUBCUT EXT REL SUSPENSION SYRINGE	QL

New Added Products: **Effective 8/1/2023**

Drug	Restrictions**
AMJEVITA(CF) 10 MG/0.2 ML SUBCUTANEOUS SYRINGE	PA QL
GEFITINIB 250 MG TABLET	PA QL

Updated: 11/1/2023

Y0026\_203589\_C

EmblemHealth Plan Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies. EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



Drug	Restrictions**
KALYDECO 13.4 MG ORAL GRANULES IN PACKET	PA QL
MEKINIST 0.05 MG/ML ORAL SOLUTION	PA QL
METHSUXIMIDE 300 MG CAPSULE	
NITISINONE 20 MG CAPSULE	PA
TAFINLAR 10 MG TABLET FOR ORAL SUSPENSION	PA QL
TRIKAFTA 100-50-75 MG (D)/75 MG (N) GRANULE PACK	PA QL
TRIKAFTA 80-40-60 MG (D)/59.5 MG (N) GRANULE PACK	PA QL
TURALIO 125 MG CAPSULE	PA QL

New Added Products: **Effective 7/1/2023**

Drug	Restrictions***
APOKYN 10 MG/ML SUBCUTANEOUS CARTRIDGE	PA QL LA
APOMORPHINE 10 MG/ML SUBCUTANEOUS CARTRIDGE	PA QL
AUGMENTIN 125 MG-31.25 MG/5 ML ORAL SUSPENSION	
LUMAKRAS 320 MG TABLET	PA
NAFTIFINE 2 % TOPICAL GEL	QL
PRIMIDONE 125 MG TABLET	
ROTARIX 10EXP6 CCID50/1.5 ML ORAL SUSPENSION	

New Added Products: **Effective 6/1/2023**

Drug	Restrictions*
DILTIAZEM ER 120 MG TABLET, EXTENDED RELEASE 24 HR	
DILTIAZEM ER 420 MG TABLET, EXTENDED RELEASE 24 HR	
ENDOCET 2.5 MG-325 MG TABLET	QL
ERLEADA 240 MG TABLET	PA QL
TERIFLUNOMIDE 14 MG TABLET	PA QL

Updated: 11/1/2023

Y0026\_203589\_C

EmblemHealth Plan Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies. EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



Drug	Restrictions*
TERIFLUNOMIDE 7 MG TABLET	PA QL

New Added Products: **Effective 5/1/2023**

Drug	Restrictions***
JAYPIRCA 100 MG TABLET	PA QL
JAYPIRCA 50 MG TABLET	PA QL
LAMOTRIGINE 25 MG (21)-50 MG (7) TABLET,DISINTEGRATING, PACK	
LAMOTRIGINE 50 MG (42)-100 MG (14) TABLET,DISINTEGRATING, PACK	
LURASIDONE 120 MG TABLET	QL
LURASIDONE 20 MG TABLET	QL
LURASIDONE 40 MG TABLET	QL
LURASIDONE 60 MG TABLET	QL
LURASIDONE 80 MG TABLET	QL
LYTGOBI 4 MG TABLET	PA LA
LYTGOBI 4 MG TABLET (16 MG DAILY DOSE)	PA LA
LYTGOBI 4 MG TABLET (20 MG DAILY DOSE)	PA LA
NEO-POLYCIN 3.5 MG-400 UNIT-10,000 UNIT/G EYE OINTMENT	
NEO-POLYCIN HC 3.5 MG-400-10,000 UNIT/G-1 % EYE OINTMENT	
ORSERDU 345 MG TABLET	PA QL
ORSERDU 86 MG TABLET	PA QL
POLYCIN 500 UNIT-10,000 UNIT/GRAM EYE OINTMENT	
REZLIDHIA 150 MG CAPSULE	PA QL
SUBVENITE 100 MG TABLET	
SUBVENITE 150 MG TABLET	
SUBVENITE 200 MG TABLET	
SUBVENITE 25 MG TABLET	
SUBVENITE STARTER (BLUE) KIT 25 MG (35) TABLETS IN A DOSE PACK	

Updated: 11/1/2023

Y0026\_203589\_C

EmblemHealth Plan Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies. EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



Drug	Restrictions***
SUBVENITE STARTER (GREEN) KIT 25 MG (84)-100 MG (14) TABLET, DOSE PACK	
SUBVENITE STARTER (ORANGE) KIT 25 MG (42)-100 MG (7) TABLET, DOSE PACK	
T AFLUPROST (PF) 0.0015 % EYE DROPS IN A DROPPERETTE	
TASIMELTEON 20 MG CAPSULE	PA QL
VELPHORO 500 MG CHEWABLE TABLET	QL
ZTALMY 50 MG/ML ORAL SUSPENSION	PA QL LA

New Added Products: **Effective 4/1/2023**

Drug	Restrictions*
AMJEVITA 20 MG/0.4 ML SUBCUTANEOUS SYRINGE	PA QL
AMJEVITA 40 MG/0.8 ML SUBCUTANEOUS SYRINGE	PA QL
AMJEVITA AUTOINJECTOR 40 MG/0.8 ML SUBCUTANEOUS AUTO-INJECTOR	PA QL
ESTRADIOL VALERATE 10 MG/ML INTRAMUSCULAR OIL	
HEPLISAV-B (PF) 20 MCG/0.5 ML INTRAMUSCULAR SYRINGE	PA
JYNNEOS(PF)(NATIONAL STOCKPILE) 0.5X TO 3.95X 10EXP8/0.5ML SUBCUT SUSP	PA
KRAZATI 200 MG TABLET	PA QL
LUBIPROSTONE 24 MCG CAPSULE	QL
LUBIPROSTONE 8 MCG CAPSULE	QL
OZEMPIC 0.25 MG OR 0.5 MG (2 MG/3 ML) SUBCUTANEOUS PEN INJECTOR	PA QL
PIRFENIDONE 267 MG CAPSULE	PA QL
SODIUM OXYBATE 500 MG/ML ORAL SOLUTION	PA QL LA
SUNLENCA 300 MG TABLET	
SUNLENCA 300 MG TABLET (4-TABLET PACK)	

New Added Products: **Effective 3/1/2023**

Updated: 11/1/2023

Y0026\_203589\_C

EmblemHealth Plan Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies. EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



Drug	Restrictions*
AMLODIPINE 10 MG-VALSARTAN 160 MG-HYDROCHLOROTHIAZIDE 12.5 MG TABLET	
AMLODIPINE 10 MG-VALSARTAN 160 MG-HYDROCHLOROTHIAZIDE 25 MG TABLET	
AMLODIPINE 10 MG-VALSARTAN 320 MG-HYDROCHLOROTHIAZIDE 25 MG TABLET	
AMLODIPINE 5 MG-VALSARTAN 160 MG-HYDROCHLOROTHIAZIDE 12.5 MG TABLET	
AMLODIPINE 5 MG-VALSARTAN 160 MG-HYDROCHLOROTHIAZIDE 25 MG TABLET	
AUVELITY 45 MG-105 MG TABLET, EXTENDED RELEASE	ST QL
GLEOSTINE 10 MG CAPSULE	
GLEOSTINE 100 MG CAPSULE	
GLEOSTINE 40 MG CAPSULE	
MENEST 2.5 MG TABLET	PA
ROFLUMILAST 250 MCG TABLET	PA QL
SKYRIZI 180 MG/1.2 ML (150 MG/ML) SUBCUTANEOUS WEARABLE INJECTOR	PA QL

New Added Products: **Effective 2/1/2023**

Drug	Restrictions*
CALQUENCE (ACALABRUTINIB MALEATE) 100 MG TABLET	PA QL LA
CAPLYTA 10.5 MG CAPSULE	QL
CAPLYTA 21 MG CAPSULE	QL
CIPRO 250 MG/5 ML ORAL SUSPENSION	
CIPRO 500 MG/5 ML ORAL SUSPENSION	
DABIGATRAN ETEXILATE 150 MG CAPSULE	
DABIGATRAN ETEXILATE 75 MG CAPSULE	
DESCOVY 120 MG-15 MG TABLET	
DOXYCYCLINE HYCLATE 100 MG TABLET	
FINGOLIMOD 0.5 MG CAPSULE	PA QL
ICOSAPENT ETHYL 0.5 GRAM CAPSULE	
IMBRUVICA 140 MG TABLET	PA QL

Updated: 11/1/2023

Y0026\_203589\_C

EmblemHealth Plan Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies. EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.



Drug	Restrictions*
IMBRUVICA 70 MG/ML ORAL SUSPENSION	PA QL
INGREZZA 40 MG CAPSULE	PA QL LA
INGREZZA 60 MG CAPSULE	PA QL LA
INGREZZA 80 MG CAPSULE	PA QL LA
INGREZZA INITIATION PACK 40 MG (7)-80 MG (21) CAPSULES IN A DOSE PACK	PA QL LA
LENALIDOMIDE 2.5 MG CAPSULE	PA QL
LENALIDOMIDE 20 MG CAPSULE	PA QL
MESALAMINE ER 500 MG CAPSULE,EXTENDED RELEASE	
ORKAMBI 75 MG-94 MG ORAL GRANULES IN PACKET	PA QL
PENCICLOVIR 1 % TOPICAL CREAM	QL
PHOSPHOLINE IODIDE 0.125 % EYE DROPS	
ROFLUMILAST 500 MCG TABLET	PA QL
SODIUM,POTASSIUM,MAG SULFATES 17.5 GRAM-3.13 GRAM-1.6 GRAM ORAL SOLN	
TAZAROTENE 0.05 % TOPICAL GEL	PA
TAZAROTENE 0.1 % TOPICAL GEL	PA
ZONISADE 100 MG/5 ML ORAL SUSPENSION	PA

Updated: 11/1/2023

Y0026\_203589\_C

EmblemHealth Plan Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies. EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.





Health Insurance Plan of Greater New York (HIP) is an HMO/HMO-POS/HMO D-SNP plan with a Medicare contract. HIP has a contract with the New York Medicaid Program for HMO D-SNP. Group Health Incorporated (GHI) is a standalone PDP with a Medicare contract. Enrollment in HIP and GHI depends on contract renewal. HIP and GHI are EmblemHealth companies.

For more information about how these changes may affect your cost-sharing, such as copayments or coinsurance, or for more information about asking for an updated coverage determination or a formulary exception, please see the plan Evidence of Coverage.

Alternative drugs are drugs in the same therapeutic category/class as the affected drug. Only your doctor can determine alternative drugs that are appropriate for you given the individualized nature of drug therapy. Please talk to your doctor about any changes or recommendations to your medical care and prescription drug therapy. Alternative drugs and additional information about formulary changes can be found on the plan formulary,

\*Indicates a restriction of Step Therapy, Prior Authorization or Quantity Limits may exist.

[LA] = Limited Access, [PA] = Prior Authorization, [QL] = Quantity Limit, [ST] = Step Therapy

Note to existing members: This formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take.

Beneficiaries must use network pharmacies to access their premium and/or copayment/coinsurance may change on January 1, 2024.

This document includes EmblemHealth Medicare HMO/PPO partial formulary as of November 1, 2023.

EmblemHealth Medicare HMO: 1-877-344-7364, Monday through Sunday, 8 am to 8 pm.

EmblemHealth Medicare PPO: 1-866-557-7300, Monday through Sunday, 8 am to 8 pm.

TTY/TDD users should call 711.

22348 v16

Updated: 11/1/2023

Y0026\_203589\_C

EmblemHealth Plan Inc., HIP Health Plan of New York (HIP), HIP Insurance Company of New York and EmblemHealth Services Company, LLC are EmblemHealth companies. EmblemHealth Services Company, LLC provides administrative services to the EmblemHealth companies.